MedTrace Logo

Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis

NCT04026360 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-11-04

No results posted yet for this study

Summary

This study collects data on microbiological factors and lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth and lung development of infants and children with Cystic Fibrosis (CF).

Conditions

  • Confirmed Diagnosis of Cystic Fibrosis

Interventions

OTHER

no intervention

Sponsors & Collaborators

  • University Children's Hospital, Zurich

    collaborator OTHER

  • Centre Hospitalier Universitaire Vaudois

    collaborator OTHER

  • Kantonsspital Aarau

    collaborator OTHER

  • University Children's Hospital Basel

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Philipp Latzin, MD PhD · University Children's Hospital Bern

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-01
Primary Completion
2050-08-31
Completion
2050-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04026360 on ClinicalTrials.gov